These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 35029330)
1. Access to early-phase clinical trials for children with relapsed and refractory neuroblastoma: A multicentre international study. Cortes M; Carceller F; Rubio-San-Simón A; Vaidya SJ; Bautista F; Moreno L Pediatr Blood Cancer; 2022 Aug; 69(8):e29551. PubMed ID: 35029330 [TBL] [Abstract][Full Text] [Related]
2. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials. Moreno L; Rubie H; Varo A; Le Deley MC; Amoroso L; Chevance A; Garaventa A; Gambart M; Bautista F; Valteau-Couanet D; Geoerger B; Vassal G; Paoletti X; Pearson AD Pediatr Blood Cancer; 2017 Jan; 64(1):25-31. PubMed ID: 27555472 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. Di Giannatale A; Dias-Gastellier N; Devos A; Mc Hugh K; Boubaker A; Courbon F; Verschuur A; Ducassoul S; Malekzadeh K; Casanova M; Amoroso L; Chastagner P; Zwaan CM; Munzer C; Aerts I; Landman-Parker J; Riccardi R; Le Deley MC; Geoerger B; Rubie H Eur J Cancer; 2014 Jan; 50(1):170-7. PubMed ID: 24021349 [TBL] [Abstract][Full Text] [Related]
4. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783 [TBL] [Abstract][Full Text] [Related]
5. Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS. Chaix J; Schleiermacher G; Corradini N; André N; Thebaud E; Gambart M; Defachelles AS; Entz-Werle N; Chastagner P; De Carli É; Ducassou S; Landman-Parker J; Adam-de-Beaumais T; Larive A; Michiels S; Vassal G; Valteau-Couanet D; Geoerger B; Berlanga P Eur J Cancer; 2024 Apr; 201():113923. PubMed ID: 38377775 [TBL] [Abstract][Full Text] [Related]
6. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. Villablanca JG; Ji L; Shapira-Lewinson A; Marachelian A; Shimada H; Hawkins RA; Pampaloni M; Lai H; Goodarzian F; Sposto R; Park JR; Matthay KK Pediatr Blood Cancer; 2018 May; 65(5):e26940. PubMed ID: 29350464 [TBL] [Abstract][Full Text] [Related]
7. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma. Mody R; Zhao L; Yanik GA; Opipari V Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436582 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pinto N; DuBois SG; Marachelian A; Diede SJ; Taraseviciute A; Glade Bender JL; Tsao-Wei D; Groshen SG; Reid JM; Haas-Kogan DA; Reynolds CP; Kang MH; Irwin MS; Macy ME; Villablanca JG; Matthay KK; Park JR Pediatr Blood Cancer; 2018 Jul; 65(7):e27023. PubMed ID: 29603591 [TBL] [Abstract][Full Text] [Related]
9. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301 [TBL] [Abstract][Full Text] [Related]
10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
11. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045 [TBL] [Abstract][Full Text] [Related]
12. Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Park JR; Villablanca JG; Hero B; Kushner BH; Wheatley K; Beiske KH; Ladenstein RL; Baruchel S; Macy ME; Moreno L; Seibel NL; Pearson AD; Matthay KK; Valteau-Couanet D Cancer; 2022 Nov; 128(21):3775-3783. PubMed ID: 36101004 [TBL] [Abstract][Full Text] [Related]
13. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555 [TBL] [Abstract][Full Text] [Related]
14. Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma. Ehlert K; Hansjuergens I; Zinke A; Otto S; Siebert N; Henze G; Lode H J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414861 [TBL] [Abstract][Full Text] [Related]
15. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475 [TBL] [Abstract][Full Text] [Related]
16. Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial. Sholler GLS; Bergendahl G; Lewis EC; Kraveka J; Ferguson W; Nagulapally AB; Dykema K; Brown VI; Isakoff MS; Junewick J; Mitchell D; Rawwas J; Roberts W; Eslin D; Oesterheld J; Wada RK; Pastakia D; Harrod V; Ginn K; Saab R; Bielamowicz K; Glover J; Chang E; Hanna GK; Enriquez D; Izatt T; Halperin RF; Moore A; Byron SA; Hendricks WPD; Trent JM Genome Med; 2024 Feb; 16(1):28. PubMed ID: 38347552 [TBL] [Abstract][Full Text] [Related]
17. A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma. Herd F; Basta NO; McNally RJQ; Tweddle DA Eur J Cancer; 2019 Apr; 111():50-58. PubMed ID: 30822684 [TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554 [TBL] [Abstract][Full Text] [Related]
19. Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. Michot JM; Benajiba L; Faivre L; Baldini C; Haddag L; Bonnet C; Massard C; Bigot F; Bigenwald C; Verret B; Thomas ZAP; Varga A; Gazzah A; Hollebecque A; Ghez D; Lazarovici J; Balheda R; Jeanson A; Postel-Vinay S; Danu A; Soria JC; Paoletti X; Ribrag V Invest New Drugs; 2018 Feb; 36(1):62-74. PubMed ID: 28597151 [TBL] [Abstract][Full Text] [Related]